Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges

被引:35
|
作者
Barro, Lassina [1 ,2 ]
Drew, Victor J. [1 ]
Poda, Ghislain G. [3 ]
Tagny, Claude T. [4 ]
El-Ekiaby, Magdy [5 ]
Owusu-Ofori, Shirley [6 ]
Burnouf, Thierry [1 ,7 ]
机构
[1] Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan
[2] Ctr Natl Transfus Sanguine, Ouagadougou, Burkina Faso
[3] Minist Hlth, Ouagadougou, Burkina Faso
[4] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon
[5] Shabrawishi Hosp, Blood Ctr, Cairo, Egypt
[6] Komfo Anokye Teaching Hosp, Transfus Med Unit, Kumasi, Ghana
[7] Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Coll Biomed Engn, 250 Wuxing St, Taipei 110, Taiwan
关键词
blood; clinical use; sub-Saharan Africa; transfusion; EBOLA-VIRUS DISEASE; CONVALESCENT PLASMA; WHOLE-BLOOD; BURKINA-FASO; WEST-AFRICA; DONORS; COMPONENTS; SERVICES; ANEMIA; SAFETY;
D O I
10.1111/vox.12705
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Blood transfusion in sub-Saharan Africa (SSA) is at a crossroad. Significant recent developments may help meet local needs in safe blood products and fulfil a global health target, as highlighted by the World Health Organization (WHO) Millennium and Sustainable Development Goals, in improving supply and safety, and ensuring the gradual implementation of selective haemotherapy. When WHO recommended the evaluation of convalescent blood or plasma to treat Ebola-infected patients during the recent epidemics, substantial gaps in local blood collection, testing and technology infrastructure and safety, as compared to best accepted quality standards, became evident. This evidence should now serve as an 'electro-shock'/awakening call used to highlight the needs for local governments to support National Blood Transfusion Services and establish robust national regulatory authorities that are mandated to bear regulatory responsibilities of blood establishments. A nationally co-ordinated blood programme is the best tool to gather reliable epidemiological data, address local needs in blood and blood products and serve public health. A literature review using WHO website and PubMed was conducted in this article to outline the current clinical use of blood products and plasma derivatives in SSA. This text also intends to highlight the gaps to be filled in the coming years with respect to quality, safety, supply and efficacy of blood and plasma products, in line with WHO guidelines for transfusion.
引用
收藏
页码:726 / 736
页数:11
相关论文
共 50 条